MBX Biosciences, Inc.

Stocks

MBX

US55287L1017

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-12 pm EDT			5-day change	1st Jan Change
35.51 ^USD	-4.67%		+17.27%	+12.59%

Jun. 12	MBX Biosciences, Inc. - Special Call
Jun. 12	MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell	MT

Transcript : MBX Biosciences, Inc. - Special Call

Published on 05/11/2026 at 12:50 pm EDT - Modified on 05/11/2026 at 08:11 pm EDT

S&P Capital IQ

Presenter Speech
Peter Hawryluk (Executives)

Welcome to everyone in the room and on webcast, and thank you for joining us for Obesity Day. Today, we are excited and honored to present our novel and

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about MBX Biosciences, Inc.

Jun. 12	MBX Biosciences, Inc. - Special Call
Jun. 12	MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell	MT
Jun. 12	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential PTH Replacement Therapy In Chronic Hypoparathyroidism	CI
May. 11	Mbx Biosciences Insider Sold Shares Worth $2,685,515, According to a Recent SEC Filing	MT
May. 11	MBX Biosciences, Inc. - Special Call
May. 11	Truist Raises Price Target on MBX Biosciences to $70 From $50, Keeps Buy Rating	MT
May. 11	MBX Biosciences, Inc. Provides Obesity Portfolio Update Including Initial Phase 1 Data For MBX 4291 Supporting Potential For Once-Monthly Dosing	CI
May. 08	Mbx Biosciences, Inc. Announces Resignation of Steven L. Hoerter from Audit Committee of the Board, Effective May 1, 2026	CI
May. 07	MBX Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 07	MBX Biosciences, Inc. Appoints Mark R. Soued as Chief Commercial Officer	CI
Apr. 22	PMV Pharmaceuticals, Inc. Announces Board Changes, Effective June 4, 2026	CI
Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Mar. 12	MBX Biosciences Q4 Net Loss Widens; Expects Cash Runway Into 2029	MT
Mar. 12	Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss	MT